S&P 500   4,589.83 (+0.48%)
DOW   36,181.88 (+0.64%)
QQQ   389.33 (+0.13%)
AAPL   191.30 (+0.71%)
MSFT   372.73 (-1.63%)
META   323.27 (-1.19%)
GOOGL   131.39 (-0.86%)
AMZN   146.49 (+0.27%)
TSLA   238.82 (-0.52%)
NVDA   469.69 (+0.43%)
NIO   7.18 (-1.24%)
BABA   73.34 (-2.06%)
AMD   120.53 (-0.52%)
T   16.64 (+0.42%)
F   10.54 (+2.73%)
MU   75.70 (-0.55%)
CGC   0.59 (+5.52%)
GE   122.91 (+0.91%)
DIS   92.35 (-0.37%)
AMC   6.78 (+1.95%)
PFE   29.39 (-3.54%)
PYPL   59.16 (+2.69%)
XOM   104.01 (+1.24%)
S&P 500   4,589.83 (+0.48%)
DOW   36,181.88 (+0.64%)
QQQ   389.33 (+0.13%)
AAPL   191.30 (+0.71%)
MSFT   372.73 (-1.63%)
META   323.27 (-1.19%)
GOOGL   131.39 (-0.86%)
AMZN   146.49 (+0.27%)
TSLA   238.82 (-0.52%)
NVDA   469.69 (+0.43%)
NIO   7.18 (-1.24%)
BABA   73.34 (-2.06%)
AMD   120.53 (-0.52%)
T   16.64 (+0.42%)
F   10.54 (+2.73%)
MU   75.70 (-0.55%)
CGC   0.59 (+5.52%)
GE   122.91 (+0.91%)
DIS   92.35 (-0.37%)
AMC   6.78 (+1.95%)
PFE   29.39 (-3.54%)
PYPL   59.16 (+2.69%)
XOM   104.01 (+1.24%)
S&P 500   4,589.83 (+0.48%)
DOW   36,181.88 (+0.64%)
QQQ   389.33 (+0.13%)
AAPL   191.30 (+0.71%)
MSFT   372.73 (-1.63%)
META   323.27 (-1.19%)
GOOGL   131.39 (-0.86%)
AMZN   146.49 (+0.27%)
TSLA   238.82 (-0.52%)
NVDA   469.69 (+0.43%)
NIO   7.18 (-1.24%)
BABA   73.34 (-2.06%)
AMD   120.53 (-0.52%)
T   16.64 (+0.42%)
F   10.54 (+2.73%)
MU   75.70 (-0.55%)
CGC   0.59 (+5.52%)
GE   122.91 (+0.91%)
DIS   92.35 (-0.37%)
AMC   6.78 (+1.95%)
PFE   29.39 (-3.54%)
PYPL   59.16 (+2.69%)
XOM   104.01 (+1.24%)
S&P 500   4,589.83 (+0.48%)
DOW   36,181.88 (+0.64%)
QQQ   389.33 (+0.13%)
AAPL   191.30 (+0.71%)
MSFT   372.73 (-1.63%)
META   323.27 (-1.19%)
GOOGL   131.39 (-0.86%)
AMZN   146.49 (+0.27%)
TSLA   238.82 (-0.52%)
NVDA   469.69 (+0.43%)
NIO   7.18 (-1.24%)
BABA   73.34 (-2.06%)
AMD   120.53 (-0.52%)
T   16.64 (+0.42%)
F   10.54 (+2.73%)
MU   75.70 (-0.55%)
CGC   0.59 (+5.52%)
GE   122.91 (+0.91%)
DIS   92.35 (-0.37%)
AMC   6.78 (+1.95%)
PFE   29.39 (-3.54%)
PYPL   59.16 (+2.69%)
XOM   104.01 (+1.24%)

Kymera Therapeutics (KYMR) Short Interest Ratio & Short Volume

$20.64
-0.12 (-0.58%)
(As of 12:03 PM ET)
Compare
Today's Range
$19.73
$20.84
50-Day Range
$10.97
$20.89
52-Week Range
$9.60
$39.85
Volume
84,051 shs
Average Volume
537,510 shs
Market Capitalization
$1.15 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$39.30

Kymera Therapeutics Short Interest Data

Current Short Volume
7,450,000 shares
Previous Short Volume
8,100,000 shares
Change Vs. Previous Month
-8.02%
Dollar Volume Sold Short
$134.77 million
Short Interest Ratio / Days to Cover
11.2
Last Record Date
November 15, 2023
Outstanding Shares
55,490,000 shares
Percentage of Shares Shorted
13.43%
Today's Trading Volume
84,051 shares
Average Trading Volume
537,510 shares
Today's Volume Vs. Average
16%
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling Kymera Therapeutics ?

Sign up to receive the latest short interest report for Kymera Therapeutics and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

KYMR Short Interest Over Time

KYMR Days to Cover Over Time

KYMR Percentage of Float Shorted Over Time


Kymera Therapeutics Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
11/15/20237,450,000 shares $134.77 million -8.0%N/A11.2 $18.09
10/31/20238,100,000 shares $94.53 million +10.7%N/A13.9 $11.67
10/15/20237,320,000 shares $92.31 million +0.4%N/A14.2 $12.61
9/30/20237,290,000 shares $101.33 million -1.8%N/A17.9 $13.90
9/15/20237,420,000 shares $141.35 million +3.6%N/A19.7 $19.05
8/31/20237,160,000 shares $136.61 million -2.3%N/A17.1 $19.08
8/15/20237,330,000 shares $143.74 million -3.9%N/A15.5 $19.61
7/31/20237,630,000 shares $166.94 million -5.5%N/A15.3 $21.88
7/15/20238,070,000 shares $178.67 million -0.6%N/A15.5 $22.14
6/30/20238,120,000 shares $186.68 million -2.3%N/A15.2 $22.99
6/15/20238,310,000 shares $229.94 million -10.1%N/A15.5 $27.67
5/31/20239,240,000 shares $272.03 million -2.0%N/A18.8 $29.44
5/15/20239,430,000 shares $281.96 million -2.0%21.3%20.8 $29.90
4/30/20239,620,000 shares $303.41 million -0.2%21.7%21.4 $31.54
4/15/20239,640,000 shares $316.77 million +0.5%21.8%21.4 $32.86
3/31/20239,590,000 shares $284.15 million +2.0%21.7%18.6 $29.63
3/15/20239,400,000 shares $292.62 million -0.6%21.3%17.6 $31.13
2/28/20239,460,000 shares $296.85 million -0.7%21.4%13.2 $31.38
2/15/20239,530,000 shares $314.49 million -1.1%21.7%13.1 $33.00
1/31/20239,640,000 shares $360.34 million +2.4%21.9%12.9 $37.38
1/15/20239,410,000 shares $325.02 million +4.6%21.4%12.3 $34.54
12/30/20229,000,000 shares $224.64 million +11.8%20.5%11.7 $24.96
12/15/20228,050,000 shares $224.60 million +9.8%18.4%10.6 $27.90
11/30/20227,330,000 shares $212.42 million -7.0%16.9%11.7 $28.98
11/15/20227,880,000 shares $236.64 million -5.6%18.1%12.3 $30.03
10/31/20228,350,000 shares $253.34 million +8.4%19.3%12.6 $30.34
10/15/20227,700,000 shares $169.40 million +1.9%18.0%11.6 $22.00
9/30/20227,560,000 shares $164.58 million +10.2%17.9%11.7 $21.77
9/15/20226,860,000 shares $197.29 million +7.7%16.2%9.9 $28.76
8/31/20226,370,000 shares $180.08 million +7.4%15.1%8.9 $28.27
8/15/20225,930,000 shares $200.08 million -3.3%14.8%8.2 $33.74
7/31/20226,130,000 shares $135.04 million -4.1%15.3%8 $22.03
7/15/20226,390,000 shares $148.44 million +10.0%16.0%8 $23.23
6/30/20225,810,000 shares $114.40 million +16.9%14.5%7.5 $19.69
6/15/20224,970,000 shares $70.47 million +1.0%12.4%6.8 $14.18
5/31/20224,920,000 shares $70.21 million -0.2%12.3%7.6 $14.27
5/15/20224,930,000 shares $85.98 million +42.5%12.3%8.4 $17.44
4/30/20223,460,000 shares $108.47 million +6.1%8.7%6.8 $31.35
4/15/20223,260,000 shares $124.01 million +7.6%8.2%8 $38.04
3/31/20223,030,000 shares $128.23 million -3.5%7.6%7.4 $42.32













KYMR Short Interest - Frequently Asked Questions

What is Kymera Therapeutics' current short interest?

Short interest is the volume of Kymera Therapeutics shares that have been sold short but have not yet been closed out or covered. As of November 15th, investors have sold 7,450,000 shares of KYMR short. Learn More on Kymera Therapeutics' current short interest.

What is a good short interest ratio for Kymera Therapeutics?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. KYMR shares currently have a short interest ratio of 11.0. Learn More on Kymera Therapeutics's short interest ratio.

Which institutional investors are shorting Kymera Therapeutics?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Kymera Therapeutics: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Is Kymera Therapeutics' short interest increasing or decreasing?

Kymera Therapeutics saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 7,450,000 shares, a drop of 8.0% from the previous total of 8,100,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does Kymera Therapeutics' short interest compare to its competitors?

Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to Kymera Therapeutics: BioCryst Pharmaceuticals, Inc. (14.39%), Relay Therapeutics, Inc. (17.28%), Inhibrx, Inc. (15.31%), Vir Biotechnology, Inc. (6.97%), SpringWorks Therapeutics, Inc. (20.39%), Editas Medicine, Inc. (19.43%), REGENXBIO Inc. (10.20%), ADMA Biologics, Inc. (4.11%), Scholar Rock Holding Co. (14.28%), Sana Biotechnology, Inc. (21.84%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: RTX Co. ($7.24 billion), T-Mobile US, Inc. ($4.02 billion), Charter Communications, Inc. ($3.72 billion), Occidental Petroleum Co. ($2.80 billion), Lululemon Athletica Inc. ($2.48 billion), Coinbase Global, Inc. ($2.38 billion), Tractor Supply ($2.35 billion), Rivian Automotive, Inc. ($1.79 billion), Royal Caribbean Cruises Ltd. ($1.73 billion), and Moderna, Inc. ($1.71 billion). View all of the most shorted stocks.

What does it mean to sell short Kymera Therapeutics stock?

Short selling KYMR is an investing strategy that aims to generate trading profit from Kymera Therapeutics as its price is falling. KYMR shares are trading down $0.29 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Kymera Therapeutics?

A short squeeze for Kymera Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of KYMR, which in turn drives the price of the stock up even further.

How often is Kymera Therapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including KYMR, twice per month. The most recent reporting period available is November, 15 2023.



More Short Interest Resources from MarketBeat

This page (NASDAQ:KYMR) was last updated on 12/1/2023 by MarketBeat.com Staff

My Account -